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ICD-9 codes were used to identify patients’ comorbidities and advanced liver 
disease complications. RESULTS: The 5-year prevalence rate (2007-2011) of 
chronic HCV among commercially-insured individuals was 0.187% (95%CI 
0.185%-0.188%). In 2011, a total of 27,843 chronic HCV patients were identified. 
The average age of these chronic HCV patients was 53 years (SD 11). Chronic HCV 
patients exhibited a wide array of health problems. The prevalence rates of 
comorbidities such as anxiety (13.5% versus 4.7%), depression (17.9% versus 
5.2%), alcohol abuse (35.3% versus 1.2%), hypertension (46.2% versus 18.6%), type 
2 diabetes (18.8% versus 6.2%), HIV (2.5% versus 0.1%), and ESRD (2.1% versus 
0.1%) were higher (all statistically significant, p<0.0001) in the chronic HCV 
population than the non-HCV population. Similarly, the 2011 prevalence rates of 
advanced liver disease were higher in the chronic HCV population (all p<0.0001), 
including non-decompensated liver disease (20.5% versus 0.1%), decompensated 
cirrhosis (15.1% versus 0.5%), hepatocellular carcinoma (3.4% versus 0.03%), and 
liver transplant (2.6% versus 0.01%). CONCLUSIONS: Chronic HCV patients have a 
wide array of significant health problems and stages of advanced liver disease 
relative to non-HCV patients.  
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SEASONAL TRENDS IN INCIDENCE OF HERPES LABIALIS (“COLD SORES”) 
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OBJECTIVES: The Internet is an important source of health information and 
Google search engine queries are an increasingly useful source of health data. 
The study objective was to analyze Google search query data about herpes labialis 
(“cold sores”) to determine if information-seeking behavior on the topic 
substantiates anecdotal evidence that herpes labialis outbreaks have cyclical, 
seasonal trends. METHODS: Google Trends provides normalized, scaled indices of 
the volume of Google search engine queries by geographic location and time. 
Using the search terms “cold sore” and “cold sores,” weekly search volume 
indices data for 2004-2012 were downloaded and aggregated into weighted mean 
monthly values in three datasets: (2) Worldwide; (2) USA; and (3) Australia. 
Descriptive statistical analyses and rankings were performed to identify/quantify 
cyclical trends (peaks/troughs) in search volume activity. RESULTS: Plots of 
search volume for herpes labialis information over time reveal striking intra-
annual cyclic patterns—moving from high search volume in fall/winter months 
to low volume in spring/summer months. December was the most frequent 
(67%) high volume search month in the Worldwide and USA analyses; most 
frequently June (67%) and May/June (equally 33%) ranked lowest. In Australia 
(with reversed, southern hemisphere seasons), search volume most frequently 
(50%) peaked in June; February was lowest (63%). Quartile analysis (i.e., “top 3 
months” in search volume frequency) showed November/December/January 
peaking in the Worldwide and USA analyses, while June/July/August 
predominated in Australia. Conversely, May/June/July and June/July/August 
ranked lowest in the Worldwide and USA analyses, respectively; 
February/March/May ranked lowest in Australia. CONCLUSIONS: Analyzing 
Internet search data provides valuable insights into health-related behavior and 
disease epidemiology. Results of this study show that Internet research activity 
about herpes labialis has intra-annual cycles, presumably motivated by actual 
outbreaks of herpes labialis and treatment needs. Results loosely correlate with 
seasons, suggesting connections between herpes labialis outbreaks and changes 
in meteorological/climatological conditions.  
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USE OF AN ELECTRONIC HEALTH RECORD (EHR) DATABASE TO STUDY DRUG 
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OBJECTIVES: Develop a methodology to characterize drug resistance among 
inpatients treated for complicated intra-abdominal infection (cIAI) using a 
hospital-based electronic health record (EHR) database. METHODS: This 
retrospective observational study used qualifying inpatient encounters between 
April 1, 2005 and March 31, 2011 in Cerner Health Facts, a de-identified database 
derived from contributing facility EHRs. cIAI encounters required a primary or 
secondary discharge diagnosis of intra-abdominal infection, a qualifying surgical 
procedure and qualifying culture (defined by source/site description and 
interpretable resistance testing) ≤2-3 days from admission. The resistant group 
needed ≥1 positive culture interpreted as resistant to at least one empiric 
antibiotic class (by Multum) based on 2009 Infectious Disease Society of America 
guidelines. A multilevel or hierarchical mixed-effects model assessed risk factors 
associated with resistance across at least two antibiotic classes. RESULTS: A total 
of 953 patients from 62 hospitals met cIAI criteria; 339 (35.6%) in the resistant 
and 614 (64.4%) in the sensitive group. Mean age was 57 years; 52% were male. 
Health care-associated infection (HAI) risk factors were more common among 
the resistant group (31.6% vs. 16.6%, P<0.001). Among the 339 patients in the 
resistant group, 48% (17% of the study population) had resistance to ≥2 guideline 
antibiotic classes. Antibiotic classes with the most resistance were first-
generation cephalosporins, quinolones and third-generation cephalosporins. 
Total charges, length of stay and in-hospital mortality were all higher in the 
resistant group, but did not reach statistical significance. Risk factors associated 
with resistance across at least two guideline empiric antibiotic classes included 
HAI status, infection at the level of the appendix, blood dyscrasias and atypical 
or metastatic neoplasms. CONCLUSIONS: Resistance to antibiotics 
recommended for empiric treatment of cIAI was common, and among those 
with resistance, nearly half had resistance across ≥2 antibiotic classes. Risk 
factors associated with multi-class resistance included HAI subgroup, 
appendicitis, blood dyscrasias and atypical/advanced cancers.  
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OBJECTIVES: Clostridium difficile-associated diarrhea (CDAD) increases the risk of 
hospital mortality. Factors associated with CDAD recurrence include renal 
impairment (RI), inflammatory bowel disease (IBD) and advanced age (≥65 y). 
These factors may also affect mortality risk; how CDAD modifies their effect on 
mortality is unknown. This cohort study analyzed these effects among 
hospitalized patients with hospital-origin CDAD (HO-CDAD) and community-
origin CDAD (CO-CDAD) vs. non-CDAD controls. METHODS: A retrospective 
analysis (4/2005-6/2011) of the Health Facts database (Cerner Corp., Kansas City, 
MO) identified hospitalized adult patients with a positive C. difficiletoxin collected 
≥48 hours (HO-CDAD) or <48 hours (CO-CDAD) after admission. Generalized 
estimating equation models measured the effects of HO- and CO-CDAD, risk 
factors (RI, IBD, age ≥65), and their interactions on hospital mortality. RESULTS: 
4,505 patients with HO-CDAD, 2,825 with CO-CDAD, and 276,486 controls were 
identified. Unadjusted hospital mortality was 13.0% in HO-CDAD, 10.7% in CO-
CDAD and 2.7% in controls. There was no interaction with Age≥65 and CDAD: the 
odds were approximately doubled regardless of CDAD status. However, the effect 
of RI on mortality in HO-CDAD was 1.35 times higher than in controls 
(interaction odds ratio [OR] =1.35; 95% CI, 1.01-1.79). Considering the interaction 
term, the overall OR of dying with RI and HO-CDAD was 1.48 (95% CI, 1.12-2.00). 
Among controls, IBD had no significant effect on mortality (OR = 0.77; 95% CI, 
0.52-1.14). The interaction term for CO-CDAD and IBD was 3.05 (95% CI, 1.20-
7.79), for an overall OR for IBD with CO-CDAD = 2.36 (95% CI, 1.08-5.14). 
CONCLUSIONS: The effect of RI and IBD on mortality varies by CDAD status. RI 
and IBD have a synergistic (multiplicative instead of additive) effect with CDAD 
on mortality; if patients develop CDAD, their risk of dying greatly increases 
versus controls.  
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OBJECTIVES: In the HAART era, timely identification and treatment of non-AIDS 
morbidities can enhance survival. Awareness of disparities in rates and causes of 
death can inform public health strategies. METHODS: Patients studied had ≥2 
visits to any of 10 HIV clinics during 1996-2009. Death rates and causes were 
stratified by age, race, sex, health care payer and calendar period; trends were 
compared using Poisson regression. RESULTS: Among 8519 patients there were 
993 deaths, 430 from AIDS, 469 from non-AIDS and 94 with unknown causes. 
Overall death rates per 100 person-years of follow-up declined during 1996-2000, 
2001-2004, and 2005-2009 from 3.85 to 2.12 to 1.33, respectively (p<0.01 for trend) 
as did AIDS death rates (1.96, 0.91, 0.33; p<0.01 for trend) and non-AIDS death 
rates (1.55, 1.09, 0.78; p<0.01 for trend). Approximately one-third (31%) of 
mortality declines during 2005-2009 were from non-AIDS death reductions and 
65% from AIDS death reductions; non-AIDS death rates remained higher than 
AIDS deaths among patients <45 (0.5 vs. 0.3, p<0.01) but not for patients ≥45 
years. Overall 2005-2009 death rates were higher among blacks than non-blacks 
(2.03 vs. 1.01, p<0.01) and among persons with public health care payers (PUB) 
than non-public payers ([nPUB], 2.66 vs. 0.60, p<0.01). During 2005-2009, non-
AIDS deaths accounted for 64.7% of deaths among blacks and 61.1% among PUB. 
More than 88% of patients received HAART during 2005-2009 in all subgroups; 
rates differed by race (85.6% among blacks, 90.0% among non-blacks, p<0.01) but 
not by payer (88.2% among PUB, 88.8% among nPUB; p = 0.57). CONCLUSIONS: In 
the HOPS, continued mortality declines resulted from decreases in non-AIDS and 
AIDS-related deaths. Excess mortality persisted among blacks and the publicly 
insured, with the majority of deaths from non-AIDS causes, suggesting that 
improved detection and management of chronic non-AIDS diseases are needed 
to achieve further mortality reductions.  
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OBJECTIVES: To estimate the budget impact of changing the market shares of 
liposomal amphotericin B (L-AmB) and amphotericin B lipid complex (ABLC) for 
the treatment of invasive fungal infections (IFIs) in a US hospital. METHODS: An 
Excel-based budget impact model was developed to estimate the costs 
associated with using L-AmB and ABLC for treating adult patients with 
